# A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe

Source: https://onco.cc/trials/nct06892522/  
OnCo record `nct06892522` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Lenalidomide, Dexamethasone, Daratumumab in multiple myeloma, run by AbbVie, now recruiting.

## Summary

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations is a phase 1/2 interventional study registered as NCT06892522 by AbbVie, with 602 participants planned, started 2025-06-30 and due to reach its primary completion in 2035-12. Interventions recorded: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06892522
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM
- Sponsor: AbbVie
- Enrolled: 602

## Sources

- ClinicalTrials.gov NCT06892522: https://clinicaltrials.gov/study/NCT06892522

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Iberdomide](https://onco.cc/drugs/iberdomide/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Mezigdomide](https://onco.cc/drugs/mezigdomide/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06892522.json